retatrutide triple agonist glp-1 gip glucagon Dual and Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data Retatrutide: Eli Lilly's GLP-1 Triple

Significant results (8-10% loss) become evident around week 12 as you reach therapeutic doses

It mimics the naturally occurring hormone glucagon-like peptide-1, which your gut releases after eating

[DOI] [PMC free article] [PubMed] [Google Scholar] [100].Aviles-Olmos I, Dickson J, Kefalopoulou Z, Djamshidian A, Ell P, Soderlund T, et al

The EMA PRAC 2024 review found no causal link between licensed GLP-1 receptor agonists and suicidal ideation or self-harm, but this conclusion cannot be directly applied to retatrutide, which has additional glucagon receptor activity and lacks its own long-term safety data

For hair loss treatments, multiple sessions may be recommended to achieve the best results

Retatrutide is still under clinical development, and while early research has shown promising results for weight management, some potential side effects have been observed in studies